Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
Mendes D, Alves C, Batel Marques F
Pharmacoepidemiol Drug Saf. 2015 Sep 16. doi: 10.1002/pds.3874.
2015
http://www.ncbi.nlm.nih.gov/pubmed/26376779